Please ensure Javascript is enabled for purposes of website accessibility

Moderna Slowed Enrollment in Its Phase 3 Coronavirus Vaccine Clinical Trial

By Brian Orelli, PhD – Updated Sep 14, 2020 at 11:55AM

You’re reading a free article with opinions that may differ from The Motley Fool’s Premium Investing Services. Become a Motley Fool member today to get instant access to our top analyst recommendations, in-depth research, investing resources, and more. Learn More

Week-over-week enrollment declined 47%.

In the last week, Moderna (MRNA -1.27%) substantially slowed enrollment in the phase 3 clinical trial testing its coronavirus vaccine, mRNA-1273. After a slight slowdown last week, the biotech took a major breather, enrolling just over half the number of participants it had enrolled in the previous week.

Date of Update Enrollment Week-Over-Week Enrollment
Aug. 28, 2020 17,458 4,264
Sept. 4, 2020 21,411 3,953
Sept. 11, 2020 23,497 2,086

Source: Moderna.

The biotech said the reason for the slower enrollment is its commitment to increase diversity in the clinical trial. The fraction of white participants being enrolled in the study has decreased over the last four weeks, from 73% to 68% to 67%, and finally down to 59% for the most recent week. Meanwhile, enrollment of Hispanic or Latino participants jumped from 17% to 22%, and Black or African Americans increased from 5% of enrollment three weeks ago to 11% of enrollment in the most recent week.

Gloved hands giving an injection into an arm

Image source: Getty Images.

Moderna is trailing Pfizer (PFE -0.16%) and BioNTech (BNTX 1.31%), which had enrolled 25,189 patients in the phase 2/3 clinical trial testing its coronavirus vaccine, BNT162b2, as of an update on Sep. 7. In terms of diversity though, Moderna is ahead with 27% of participants coming from diverse communities, compared to Pfizer and BioNTech's 24%.

Fortunately for Moderna, the last few participants enrolled in the 30,000-patient study don't have much of an effect on the initial efficacy readout. Participants being enrolled now will get their booster shot four weeks from now and will start contributing to the efficacy readout -- whether they get COVID-19 -- two weeks after that. By comparison, patients enrolled early in the study, which started in late July, are starting to contribute to the efficacy readout now.

Brian Orelli, PhD and The Motley Fool have no position in any of the stocks mentioned. The Motley Fool has a disclosure policy.

Invest Smarter with The Motley Fool

Join Over 1 Million Premium Members Receiving…

  • New Stock Picks Each Month
  • Detailed Analysis of Companies
  • Model Portfolios
  • Live Streaming During Market Hours
  • And Much More
Get Started Now

Stocks Mentioned

Moderna Inc. Stock Quote
Moderna Inc.
$173.15 (-1.27%) $-2.23
Pfizer Stock Quote
$49.49 (-0.16%) $0.08
BioNTech SE Stock Quote
BioNTech SE
$163.61 (1.31%) $2.12

*Average returns of all recommendations since inception. Cost basis and return based on previous market day close.

Related Articles

Motley Fool Returns

Motley Fool Stock Advisor

Market-beating stocks from our award-winning analyst team.

Stock Advisor Returns
S&P 500 Returns

Calculated by average return of all stock recommendations since inception of the Stock Advisor service in February of 2002. Returns as of 11/30/2022.

Discounted offers are only available to new members. Stock Advisor list price is $199 per year.

Premium Investing Services

Invest better with The Motley Fool. Get stock recommendations, portfolio guidance, and more from The Motley Fool's premium services.